相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse
Joseph Moore et al.
LEUKEMIA RESEARCH (2006)
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer
MM Mita et al.
ANNALS OF ONCOLOGY (2006)
Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
AW Tolcher et al.
CLINICAL CANCER RESEARCH (2005)
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study
G von Minckwitz et al.
ANNALS OF ONCOLOGY (2005)
A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the Bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer
AW Tolcher et al.
CLINICAL CANCER RESEARCH (2004)
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment
S Hopkins-Donaldson et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
International expert panel on the use of primary (Preoperative) systemic treatment of operable breast cancer: Review and recommendations
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Oblimersen sodium (G3139 bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: A targeted approach to enhance apoptosis
SR Frankel
SEMINARS IN ONCOLOGY (2003)
Oblimersen bcl-2 antisense: Facilitating apoptosis in anticancer treatment
RJ Klasa et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
H Miayake et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Genetic analysis of chemoresistance in primary murine lymphomas
CA Schmitt et al.
NATURE MEDICINE (2000)
分享论文
